Growth Hormone Treatment Adherence in Prepubertal and Pubertal Children with Different Growth Disorders

Klaus Hartmann a, Jochen Ittner b, Elke Müller-Rossberg c, Eckhard Schönau d, Roger Stephan e, K.-Peter Ullrich f, Bernd Hoppe g, Rene Ramseger h, Jürgen Brämswig i

a Medical Centre of Childhood and Adolescence, Frankfurt, b Endokrinologische Praxis, Augsburg, c Klinikum Esslingen, Esslingen, d Universität Zu Köln, Köln, e Kinderärztliche Praxis Dres., Hildesheim, f FZMB, Bad Langensalza, g Division of Paediatric Nephrology, Department of Paediatrics, University of Bonn, Bonn, h Merck Serono GmbH, Darmstadt, and i Universitäts-Kinderklinik, Münster, Germany

Key Words
Growth hormone treatment · Recombinant human growth hormone · Compliance · Children and adolescents · easypod™ · Saizen® · Adherence

Abstract
Background/Aims: Treatment of children with growth disorders with recombinant human growth hormone is necessary for improved outcomes, including final height. Methods: Adherence data from the Observational Study Saizen®-online, recorded with the easypod™ device collected between October 2009 and May 2011, were analyzed in pediatric patients receiving recombinant human growth hormone treatment for a variety of growth disorders. Results: Data from 75 children (46 boys, 29 girls) with different growth disorders were analyzed over a period of 343 ± 201 (SD) days. Boys and girls showed similar mean ± SD adherence rates of 90.5 ± 3.1% and 92.2 ± 10.7%, respectively. Pubertal children (n = 41) had a significantly lower adherence rate (89.1 ± 13.7%) than prepubertal children (n = 29) (96.5 ± 3.9%; p < 0.005). There were nonsignificant differences in adherence rates according to diagnosis: growth hormone deficiency (n = 48) 91.4 ± 11.0%, small for gestational age (n = 18) 91.1 ± 15.3%, Turner syndrome (n = 6) 86.0 ± 14.5%, and chronic renal failure (n = 3) 99.3 ± 1.0%, although the latter two groups were small. Conclusion: Our data indicate that only a small number of pediatric patients using the easypod device had poor adherence to treatment. Further reliable adherence data are required to identify factors affecting long-term adherence in this population.

Copyright © 2013 S. Karger AG, Basel

Introduction

Human growth hormone (hGH), somatotropin, is a polypeptide hormone consisting of 191 amino acids produced by the pituitary gland. hGH is essential in the growth and maturation process of children and is also physiologically important in adults [1].

Pituitary-derived hGH has been used since the 1950s [2]. With the availability of recombinant hGH (rhGH) from 1985 [3, 4], it has become possible to treat greater
numbers of patients for a wider range of growth disorders. rhGH is used to treat growth hormone deficiency (GHD) in children and adults, and to promote growth in children with Turner syndrome (TS), chronic renal failure (CRF) and idiopathic short stature, and children born small for gestational age (SGA) who fail to demonstrate catch-up growth [5].

There are few published studies relating adherence with rhGH treatment to clinical outcome (final height) in GHD [6–9]; but to achieve an optimal growth response during rhGH therapy, it is important that children adhere to the prescribed GH dose [10–12]. Maintaining adherence to rhGH treatment is difficult as the short-term burden of daily injection administration is often more apparent than the long-term benefits of therapy. Furthermore, assessing adherence is difficult and few reliable data exist on the adherence rate of this cost-intensive treatment. Differences in adherence rates observed between studies may in part be linked to the different methods used to quantify adherence. Cutfield et al. [9] calculated the prescribed versus consumed dose in a cohort of 150 patients and observed that 66% of patients were less than 85% adherent over a 4-month period, and these patients were defined as noncompliant.

In 2007, an electronic autoinjector device (easypod™, Merck Serono S.A., Geneva, Switzerland) was introduced for the administration of rhGH (Saizen®, Merck Serono S.A.) [13, 14]. easypod is a hidden-needle autoinjector device that records the date and time of injection, prescribed dose (mg), injected dose (mg) and injection status (dose setting, performed, missed or partial injection). Owing to the electronic registration of each rhGH injection, patient adherence can be monitored accurately [14]. The device has been well accepted by patients, with 98% of survey respondents in one study reporting a ‘good’ or ‘very good’ overall impression of this device [13], and 90% of children in another study wanting to continue using the device [15].

The electronic Observational Study (OS) Saizen®-online is an observational study to evaluate the long-term efficacy of Saizen in adult and pediatric patients. Here we report data from pediatric patients administering rhGH with the easypod device in order to evaluate rhGH therapy adherence in children and adolescents with different growth disorders.

Methods

OS Saizen-online is a prospective, multicenter, open-label, non-interventional study evaluating rhGH therapy in pediatric patients with GHD, TS or CRF, those born SGA and adults with severe GHD. The primary aim of this observational study is to collect long-term efficacy data for rhGH therapy in routine clinical use, in patients for periods of up to 15 years. Patients already receiving Saizen (somatotropin for injection, Merck Serono S.A.) or in whom the clinical decision had already been made to initiate Saizen treatment were eligible for inclusion. Patient recruitment began in 2007 and is planned to continue until 2016, with the study ending in 2031. Yearly interim analyses are planned, with the final analysis conducted at study completion in 2031. This paper reports on a secondary endpoint: the collection of pediatric adherence data.

This study was performed in accordance with sections 4 (23) and 67 (6) of the German Medicines Act and notified to the appropriate German federal authorities [16].

Data Collection

Adherence data were collected from pediatric patients receiving rhGH therapy using the easypod administration device in conjunction with the clinical kit software. The easypod data from individual patients attending 11 pediatric endocrinology centers in Germany from October 2009 to May 2011 were uploaded to the internet-based Saizen electronic data capture system (SAIZEN-EDC). In addition, data on demographics, medical history, height (cm) and growth velocity (GV, cm/year) were extracted from the SAIZEN-EDC database.

Data sets with dates prior to 2009 (prior to the introduction of easypod clinical kit software), data with more than one injection per day (unless verified), and erroneously prescribed doses of 0 mg and incomplete data sets were excluded from this evaluation. Adherence was assessed with respect to the proportion of actual injected rhGH per patient as recorded by easypod compared with the prescribed dose (amount of GH administered [mg] ÷ amount of GH prescribed [mg]).

Analyses

Data analyses and calculations for adherence, GV and height standard deviation score (SDS) were performed by extracting the individual data from the SAIZEN-EDC system. Statistical analysis was performed using SAS-9.1 (SAS Institute, Cary, N.C., USA). Height SDS was calculated as (height – mean)/SD, where mean and SD were obtained from height reference ranges for Germany [17]. Only descriptive statistics were planned; any statistical testing was exploratory. Statistical analysis was performed using one-sided Student’s t test and all calculated values were expressed as mean and SD unless stated otherwise.

In addition, data were evaluated in accordance with compliance as defined by Cutfield et al. [9]: good compliance, fewer than 1 missed dose per week (85.7–100% proportion injected); medium compliance, 1–3 missed doses per week (57.1–85.7% proportion injected), and poor compliance, more than 3 missed doses per week (<57.1% proportion injected).

Pubertal Status

Clinical signs of puberty were collected to allow differentiation between prepubertal and pubertal children. Prepubertal was defined as absence of pubic hair development and testis volume less than 3 ml for males, and absence of pubic hair and breast development for females. Pubertal males were defined as those with pubic hair development or testis volume more than 3 ml, and pubertal females were defined as those with pubic hair or breast development.
Results

Patients

At the time of analysis, 1,365 patients were included in the registry, of whom 101 had clinical kit data available for evaluation. Data from 75 patients (46 male, 29 female) were evaluated after excluding 26 data sets for reasons described earlier. Patients had a mean (± SD) age of 12.5 ± 3.5 years and a mean height SDS of −2.5 ± 1.1 at the start of the adherence monitoring period (table 1). Forty-eight patients were diagnosed with GHD, 18 with SGA, 6 with TS and 3 with CRF; 29 patients were prepubertal, 41 were pubertal and pubertal status was unavailable for the remaining 5 patients. The mean ± SD prescribed somatropin dose was 0.035 ± 0.008 mg/kg/day and the average observation time was 343 ± 201 days (range 28–1,034 days).

Baseline GV and Height SDS

Overall, mean (± SD) GV was 6.9 ± 2.8 cm/year at the beginning of the adherence monitoring period (table 1). Boys had a higher GV than girls, and pubertal children had a higher GV than prepubertal children, but exploratory analyses showed no statistical differences in GV. GV was lowest in the TS and CRF groups (4.2 ± 3.2 and 2.9 ± 0.4 cm/year, respectively). Statistical analysis by diagnosis was not performed owing to small group numbers.

Female patients (height SDS −2.9 ± 1.1) were significantly shorter than male patients (−2.2 ± 1.1; p < 0.026). Prepubertal children had a lower height SDS (−2.7 ± 1.0) than pubertal children (−2.4 ± 1.2), but the difference was not relevant (table 1). Patients with TS were more severely affected in terms of height SDS than were patients with other diagnoses.

Adherence Rates

Adherence data are summarized in table 2. The mean (±SD) rhGH therapy adherence rate of all patients was 91.2 ± 12.2%. Adherence in males and females was similar – 90.5 ± 13.1% and 92.2 ± 10.7%, respectively. Prepubertal children had the highest mean adherence rate of 96.5 ± 3.9%, which was significantly higher than the rate of 89.1 ± 13.7% seen in pubertal children (p < 0.005). However, median adherence rates of prepubertal (97.4%) and pubertal patients (95.1%) were similar.

There were no relevant differences in adherence rates with respect to diagnosis. The lowest rate was observed in the group of 6 patients with TS, with a low mean (86.0 ± 14.5%) and median (87.8%) adherence rate.

Post hoc intraindividual comparison of GV and adherence rate for prepubertal and pubertal children revealed no significant correlation (data not shown).

Adherence Categories

When analyzed categorically according to the definitions of Cutfield et al. [9], 2.7% of all patients had poor compliance, 18.7% had medium compliance, and 78.7% had good compliance. Compliance was similar between boys and girls. Pubertal status revealed some differences, with 96.6% of prepubertal children categorized as good and the rest as medium compliers. Only 70.7% of pubertal children were good compliers (24.4% medium, 4.9% poor).

---

Table 1. Auxological characteristics of children treated with growth hormone

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Age, years</th>
<th>Height SDS</th>
<th>Growth velocity, cm/year</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>75</td>
<td>12.5 (3.5)</td>
<td>−2.5 (1.1)</td>
<td>6.9 (2.8)</td>
</tr>
<tr>
<td>Male</td>
<td>46</td>
<td>13.3 (3.3)</td>
<td>−2.2 (1.1)</td>
<td>7.4 (2.7)</td>
</tr>
<tr>
<td>Female</td>
<td>29</td>
<td>11.3 (3.5)</td>
<td>−2.9 (1.1)</td>
<td>6.2 (2.9)</td>
</tr>
<tr>
<td>Prepubertal</td>
<td>29</td>
<td>10.0 (3.4)</td>
<td>−2.7 (1.1)</td>
<td>7.4 (2.9)</td>
</tr>
<tr>
<td>Pubertal</td>
<td>41</td>
<td>14.5 (1.6)</td>
<td>−2.4 (1.2)</td>
<td>6.8 (2.6)</td>
</tr>
</tbody>
</table>

Diagnosis

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>n</th>
<th>Age, years</th>
<th>Height SDS</th>
<th>Growth velocity, cm/year</th>
</tr>
</thead>
<tbody>
<tr>
<td>GHD</td>
<td>48</td>
<td>13.4 (2.9)</td>
<td>−2.2 (1.1)</td>
<td>7.3 (2.5)</td>
</tr>
<tr>
<td>SGA</td>
<td>18</td>
<td>11.0 (4.0)</td>
<td>−2.8 (1.1)</td>
<td>7.5 (2.9)</td>
</tr>
<tr>
<td>TS</td>
<td>6</td>
<td>11.3 (4.8)</td>
<td>−3.4 (1.4)</td>
<td>4.2 (3.2)</td>
</tr>
<tr>
<td>CRF</td>
<td>3</td>
<td>10.4 (1.2)</td>
<td>−2.9 (0.0)</td>
<td>2.9 (0.4)</td>
</tr>
</tbody>
</table>

All values shown as mean (SD). Pubertal status was unavailable for 5 patients.

Table 2. Adherence of children with different growth disorders treated with growth hormone

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>Mean (SD), %</th>
<th>Median, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>75</td>
<td>91.2 (12.2)</td>
<td>96.0</td>
</tr>
<tr>
<td>Male</td>
<td>46</td>
<td>90.5 (13.1)</td>
<td>95.2</td>
</tr>
<tr>
<td>Female</td>
<td>29</td>
<td>92.2 (10.7)</td>
<td>96.4</td>
</tr>
<tr>
<td>Prepubertal</td>
<td>29</td>
<td>96.5 (3.9)</td>
<td>97.4</td>
</tr>
<tr>
<td>Pubertal</td>
<td>41</td>
<td>89.1 (13.7)</td>
<td>95.1</td>
</tr>
</tbody>
</table>

Diagnosis

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>n</th>
<th>Mean (SD), %</th>
<th>Median, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>GHD</td>
<td>48</td>
<td>91.4 (11.0)</td>
<td>95.5</td>
</tr>
<tr>
<td>SGA</td>
<td>18</td>
<td>91.1 (15.3)</td>
<td>96.0</td>
</tr>
<tr>
<td>TS</td>
<td>6</td>
<td>86.0 (14.5)</td>
<td>87.8</td>
</tr>
<tr>
<td>CRF</td>
<td>3</td>
<td>99.3 (1.0)</td>
<td>99.6</td>
</tr>
</tbody>
</table>

Pubertal status was unavailable for 5 patients.
4 poor; fig. 1a). Children with GHD showed poor compliance (fig. 1b), with only 77.1% of patients showing good compliance.

**Discussion**

The data presented here indicate that mean adherence in children treated with rhGH using the easypod device is good, with 91.2% of injections administered as prescribed. According to the compliance categories defined by Cutfield et al. [9], 78.7% of the patients in our study showed good compliance and 21.4% were defined as having poor compliance.

Previous studies have described almost one quarter of rhGH-treated patients as missing more than two injections per week [11] or otherwise as noncompliant [18]. Cutfield et al. [9] described 66% of all patients as noncompliant (i.e., missing one or more injection per week) over a 4-month study period. In addition, Kappelgaard and Laursen [19] reported in a recent review that up to 50% of children with TS and SGA were noncompliant with GH therapy. Part of the variation in reported compliance rates may be due to the method by which compliance is assessed. In the study by Cutfield et al. [9] there were large variations between subjective (parent-reported) and objective (empty vial count) compliance rates. Parent-reported noncompliance was 34% and returned vial count noncompliance showed 66% of patients as missing more than one dose per week. Similarly, a large-scale easypod user survey conducted over a 3-month period found that patient-reported compliance was higher than recorded compliance (90.2 vs. 87.5%) [15], demonstrating the usefulness of a device to collect objective data.

It may be possible that the relatively high compliance rates seen in studies with the easypod device are at least partly driven by patients knowing that injection data can be monitored each time they visit the clinic, and can be easily compared with self-reported data.

Our results showed little effect of diagnosis on adherence in patients with GHD or SGA. Lower adherence was detected in patients with TS, but it should be noted that there were only 6 patients in this group. In contrast, pubertal children showed significantly reduced adherence to rhGH therapy compared with prepubertal children (p < 0.005). This is not an uncommon observation [10, 18].

Poor adherence may be a result of poor education, psychological and emotional problems, social problems or technical handling issues of the drug delivery device [20]. According to the retrospective survey of Rosenfeld and Bakker [18], noncompliance was associated with misconceptions about consequences of missed doses, discomfort with injections, dissatisfaction with results, and inadequate contact with healthcare professionals.

Compliance rates with self-administered injectable therapies in diseases such as diabetes and multiple sclerosis are typically about 60–70% [21, 22]. The adherence rates measured in this study (91.2%) and in another larger study using the easypod device (87.5%) [15] are higher, as are adherence rates among patients with multiple sclerosis using the similar RebiSmart™ device [23]. This may be because the patient knows that his/her injection history can be monitored accurately. The reproducibility of injection depth and duration with an autoinjector device is another important factor in treatment adherence, in that the patient can be confident that the full dose has been administered correctly on every occasion [24] rather than suffering from incomplete dosing (and therefore reduced adherence with the prescribed dose) through poor injection technique. In their report in 2003 [25], the World Health Organization called for strategies to improve adherence, stating that health systems and provid-

---

**Fig. 1.** Compliance rates (based on Cutfield et al. [9]) for children treated with growth hormone.
Growth Hormone Treatment Adherence in Prepubertal and Pubertal Children

Horn Res Paediatr 2013;80:1–5
DOI: 10.1159/000351800


18 Rosenfeld RG, Bakker B: Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr Pract 2008;14:143–154.


References


Growth Hormone Treatment Adherence in Prepubertal and Pubertal Children

Acknowledgments

The study was sponsored by Merck Serono GmbH Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Editorial support in the form of writing and collating author comments was provided by Jackie Marchington, PhD (Caudex Medical, Oxford, UK), and funded by Merck Serono GmbH.

Disclosure Statement

J.B., J.J., K.P.U., R.S., E.M.R., and B.H. have nothing to disclose. E.S. has received honoraria or consultation fees from Bayer, Eli Lilly, Ferring, Ipsen, Pfizer, Merck Serono, NovoNordisk; R.R. is an employee of Merck Serono GmbH; K.P.H. has received financial support for this study and others from Merck Serono GmbH.

E.S. has received honoraria or consultation fees from Bayer, Eli Lilly, Ferring, Ipsen, Pfizer, Merck Serono, NovoNordisk; R.R. is an employee of Merck Serono GmbH; K.P.H. has received financial support for this study and others from Merck Serono GmbH.

E.S. has received honoraria or consultation fees from Bayer, Eli Lilly, Ferring, Ipsen, Pfizer, Merck Serono, NovoNordisk; R.R. is an employee of Merck Serono GmbH; K.P.H. has received financial support for this study and others from Merck Serono GmbH.